CN219089894U

CN219089894U - Cornea administration device

Info

Publication number: CN219089894U
Application number: CN202223500740.0U
Authority: CN
Inventors: 胡雅斌; 翟长斌; 郑燕
Original assignee: Beijing Tongren Hospital
Current assignee: Beijing Tongren Hospital
Priority date: 2022-12-27
Filing date: 2022-12-27
Publication date: 2023-05-30
Anticipated expiration: 2032-12-27

Abstract

The embodiment of the utility model discloses a cornea drug delivery device, which comprises an annular body and a handle, wherein the annular body comprises a second drug collecting part close to an eyeball and a first drug collecting part far away from the eyeball, the first drug collecting part is provided with a first drug collecting cavity, a drug adding port and a connecting port which are communicated with the first drug collecting cavity, the second drug collecting part is connected with the first drug collecting part, the second drug collecting part is provided with a second drug collecting cavity which is communicated with the connecting port and a drug collecting port which is communicated with the second drug collecting cavity, the second drug collecting part is provided with an annular bonding surface at the drug collecting port, the handle is connected with the annular body, an air cavity is arranged in the handle, the annular bonding surface is provided with an air port which is communicated with the air cavity, the handle is an elastomer, the volume of the air cavity can be changed by extruding the handle, so that the annular bonding surface can be adsorbed on the eyeball, the cornea drug delivery device is convenient to install and use, and the cornea drug delivery device can avoid solution loss and enhance the absorption efficiency of cornea, and further enhance the crosslinking effect.

Description

Cornea administration device

Technical Field

The utility model relates to the technical field of cornea crosslinking, in particular to a cornea drug delivery device.

Background

The keratoplasty is an operation for improving the hardness of cornea and changing its biological properties by inducing the mutual crosslinking of collagen fibers of the stroma of cornea by ultraviolet rays and riboflavin solution, and is used for treating keratoconus, dilated cornea and other diseases. The absorption of riboflavin solution by the cornea affects the crosslinking effect, and although many techniques exist today to effectively induce the immersion of riboflavin into the cornea, in actual surgical procedures, due to the limitations imposed by various factors, medical personnel tend to simply drip riboflavin solution intermittently onto the cornea. The administration mode easily causes the loss of the riboflavin solution, the absorption efficiency of cornea is low, and the crosslinking effect is not ideal.

Disclosure of Invention

The utility model aims to provide a cornea drug delivery device, which aims to solve the problems of low absorption efficiency of cornea and unsatisfactory crosslinking effect caused by the existing drug delivery mode.

In order to solve the above technical problems, the present utility model provides a cornea administration apparatus comprising: the device comprises an annular body and a handle, wherein the annular body comprises a second medicine collecting part close to an eyeball and a first medicine collecting part far away from the eyeball, the first medicine collecting part is provided with a first medicine collecting cavity, a medicine adding port and a connecting port, the medicine adding port and the connecting port are communicated with the first medicine collecting cavity, the second medicine collecting part is connected with the first medicine collecting part, the second medicine collecting part is provided with a second medicine collecting cavity communicated with the connecting port and a medicine collecting port communicated with the second medicine collecting cavity, the second medicine collecting part is provided with an annular fitting surface at the medicine collecting port, and the handle is connected with the annular body;

the handle is internally provided with an air cavity, the annular fitting surface is provided with an air port communicated with the air cavity, the handle is an elastomer, and the volume of the air cavity can be changed by extruding the handle, so that the annular fitting surface can be adsorbed to the eyeball.

In one embodiment, an air channel is arranged in the second medicine collecting part, and the air channel is communicated with the air port and the air cavity.

In one embodiment, the plurality of air ports are arranged and distributed at intervals in the circumferential direction of the annular fitting surface.

In one embodiment, the air passage is annular and communicates with each of the air ports.

In one embodiment, the air port is arc-shaped and extends along the circumferential direction of the annular fitting surface.

In one embodiment, the spacing between each two adjacent gas ports is equal.

In one embodiment, the annular attaching surface is an arc surface so as to be attached to the eyeball.

In one embodiment, the annular abutment surface is a structural member made of a flexible material.

In one embodiment, the first medicine collecting cavity is funnel-shaped, and the diameter of the first medicine collecting cavity gradually decreases from the medicine adding port to the connection port.

In one embodiment, the second medicine collecting portion is annular, and the second medicine collecting portion has an inner diameter of 9.0mm and an outer diameter of 13.0mm.

The embodiment of the utility model has the following beneficial effects:

the cornea administration device comprises a first medicine collecting part and a second medicine collecting part, wherein the first medicine collecting part is far away from an eyeball, the first medicine collecting part is provided with a first medicine collecting cavity, a medicine adding port and a connecting port, the medicine adding port is communicated with the first medicine collecting cavity, medical staff can drop riboflavin solution into the first medicine collecting cavity through the medicine adding port, the second medicine collecting part is provided with a second medicine collecting cavity communicated with the connecting port, the medicine collecting port is communicated with the second medicine collecting cavity, the second medicine collecting cavity is communicated with the first medicine collecting cavity, the second medicine collecting part is provided with an annular attaching surface at the medicine collecting port so as to attach the cornea administration device to the eyeball, the cornea is soaked in riboflavin solution in the second medicine collecting cavity, the handle is connected with the annular body so as to be convenient to hold the cornea, the annular attaching surface is provided with an elastic body, the handle is extruded, the volume of the air cavity can be changed, the annular attaching surface can be adsorbed on the eyeball so as to be convenient for the cornea administration device to install and use, and the cornea solution can be prevented from losing and absorbing effect can be further improved by adopting the device.

Drawings

In order to more clearly illustrate the embodiments of the utility model or the technical solutions in the prior art, the drawings that are required in the embodiments or the description of the prior art will be briefly described, it being obvious that the drawings in the following description are only some embodiments of the utility model, and that other drawings may be obtained according to these drawings without inventive effort for a person skilled in the art.

Wherein:

fig. 1 is a schematic view of an embodiment of a corneal drug delivery device.

Fig. 2 is a cross-sectional view of the corneal drug delivery device shown in fig. 1.

Fig. 3 is a schematic illustration of the flow of gas from the venting of the air chamber of the corneal administration device of fig. 1.

Fig. 4 is another angular schematic view of the corneal drug delivery device of fig. 1.

Fig. 5 is another schematic view of the corneal delivery device of fig. 1 at a second angle.

Fig. 6 is another angular schematic view of the corneal drug delivery device of fig. 1.

Fig. 7 is another angular schematic view of the corneal drug delivery device of fig. 1.

Fig. 8 is a hand-held schematic view of the corneal drug delivery device of fig. 1.

Fig. 9 is a schematic view of the cornea administration device shown in fig. 1, attached to an eyeball.

Reference numerals:

100. a first medicine collecting portion; 110. a first medicine collecting cavity; 120. a medicine adding port;

200. a second medicine collecting section; 210. a second medicine collecting cavity; 220. a medicine collecting port; 230. an airway; 240. an annular bonding surface; 250. an air port;

300. a handle; 310. an air cavity;

400. an eyeball; 410. the cornea.

Detailed Description

The following description of the embodiments of the present utility model will be made clearly and completely with reference to the accompanying drawings, in which it is apparent that the embodiments described are only some embodiments of the present utility model, but not all embodiments. All other embodiments, which can be made by those skilled in the art based on the embodiments of the utility model without making any inventive effort, are intended to be within the scope of the utility model.

It should be noted that all directional indicators (such as up, down, left, right, front, and rear … …) in the embodiments of the present utility model are merely used to explain the relative positional relationship, movement, etc. between the components in a specific posture (as shown in the drawings), and if the specific posture is changed, the directional indicators are correspondingly changed.

Furthermore, the description of "first," "second," etc. in this disclosure is for descriptive purposes only and is not to be construed as indicating or implying a relative importance or implicitly indicating the number of technical features indicated. Thus, a feature defining "a first" or "a second" may explicitly or implicitly include at least one such feature. In addition, the technical solutions of the embodiments may be combined with each other, but it is necessary to base that the technical solutions can be realized by those skilled in the art, and when the technical solutions are contradictory or cannot be realized, the combination of the technical solutions should be considered to be absent and not within the scope of protection claimed in the present utility model.

The ultraviolet A riboflavin cornea crosslinking therapy is a method for inducing the mutual crosslinking of cornea stroma collagen fibers by using 370nm ultraviolet A light and a photosensitizer riboflavin, thereby improving the cornea hardness and changing the biological performance, and is used for treating keratoconus diseases, dilated cornea diseases and the like. The photosensitizer riboflavin, vitamin B2, is excited to a triplet state under the action of ultraviolet light with the wavelength of 370nm, and generates active oxygen groups mainly containing singlet oxygen. The active oxygen group can react with various molecules to induce II-type photochemical crosslinking reaction between amino groups of the collagen fibers, so that covalent bonding can be generated between cornea fibers, covalent connection of the cornea collagen fibers is increased, the diameter of the collagen fibers is increased, the hardness of cornea tissues is increased, and the biomechanical strength and the biological stability of the collagen fibers are improved, thereby increasing the mechanical strength and the capability of resisting cornea expansion of the collagen fibers, and the collagen fiber is mainly used for treating diseases such as keratoconus, bullous keratopathy, keratitis and the like which cause cornea biomechanical degradation.

The 370nm is the absorption peak wavelength of the riboflavin, so that the absorption condition of the riboflavin has a great influence on the crosslinking result, and although various technologies such as continuous ultrasonic induction and iontophoresis are proved to be effective in inducing the riboflavin to be immersed in the cornea matrix, in the actual operation process, the riboflavin is often only simply dripped on the cornea in an intermittent manner, but the cornea is in a form of a central high periphery, so that the preparation is unevenly distributed and easily lost, the coverage area and the effective concentration of the riboflavin preparation are reduced, the absorption efficiency is quite low, and the final crosslinking effect is not ideal. The tight connection of the corneal epithelial cells causes that the riboflavin solution is difficult to permeate into the corneal stromal cells, the absorption of the riboflavin solution determines the final effect of crosslinking to a large extent, the adopted mode is quite simple in view of the fact that the operation is different from research, the riboflavin solution is dripped, most of the riboflavin is directly lost and wasted, the riboflavin can be absorbed into the stroma, the limbus is not protected in the process of dripping the riboflavin solution in the actual operation, and the final operation effect is difficult to control. Meanwhile, although the ultraviolet light A has obvious prevention and treatment effects on keratoconus, the ultraviolet light A and a chemical permeation promoter used in the operation have certain tissue toxicity, and can cause damage to limbal stem cells, thereby influencing healing and recovery of cornea epithelium after the operation.

Referring to fig. 1 to 9, the cornea administration device of an embodiment includes an annular body and a handle 300, the annular body includes a second medicine collecting portion 200 close to an eyeball 400 and a first medicine collecting portion 100 far from the eyeball 400, the first medicine collecting portion 100 is provided with a first medicine collecting cavity 110, a medicine adding port 120 and a connecting port which are communicated with the first medicine collecting cavity 110, the second medicine collecting portion 200 is connected with the first medicine collecting portion 100, the second medicine collecting portion 200 is provided with a second medicine collecting cavity 210 which is communicated with the connecting port, and a medicine collecting port 220 which is communicated with the second medicine collecting cavity 210, the second medicine collecting portion 200 is formed with an annular bonding surface 240 at the medicine collecting port 220, the handle 300 is connected with the annular body, wherein an air cavity 310 is arranged in the handle 300, an air port 250 which is communicated with the air cavity 310 is formed on the annular bonding surface 240, the handle 300 is an elastomer, and the volume of the air cavity 310 can be changed by squeezing the handle 300 so as to be capable of adsorbing the annular bonding surface 240 to 400.

In this embodiment, the thickness of the first medicine collecting portion 100 is 1.0mm. The medicine adding port 120, the connection port and the medicine collecting port 220 are all round. The plane of the medicine adding port 120 is parallel to the plane of the connecting port, the plane of the connecting port is parallel to the plane of the medicine collecting port 220, and the medicine adding port 120, the connecting port and the medicine collecting port 220 are arranged oppositely so as to facilitate the circulation of riboflavin solution in the cornea medicine feeding device. The height of the annular body is 10mm.

The handle 300 is connected to both the first medicine collecting portion 100 and the second medicine collecting portion 200. The air chamber 310 has a cylindrical shape and extends in the extending direction of the handle 300. By squeezing the handle 300 and changing the volume of the air chamber 310, the air within the air chamber 310 can be exhausted from the air port 250. Then, the annular bonding surface 240 bonded to the surface of the eyeball 400 can be adsorbed by the air pressure inside and outside the air cavity 310, so that the cornea administration device is fixed, and the cornea administration device displacement caused by the movement of the eyeball 400 of the patient is prevented. The cornea dosing device can limit the riboflavin solution in the second medicine collecting cavity 210, and soak the cornea 410, so that the riboflavin solution is uniformly covered, and meanwhile, the effective concentration is kept higher, the absorptivity and the absorption effect of the cornea 410 on the riboflavin solution are improved, the leakage and the loss of the riboflavin solution are reduced, and the damage to other parts of the eyeball 400, which may be caused by the riboflavin solution, is avoided. Furthermore, the cornea administration device can also shield other parts of the eyeball 400, prevent the eyeball from being directly irradiated by ultraviolet rays and promote postoperative recovery.

The cornea administration device can be made of polymethyl methacrylate, and the polymethyl methacrylate has light weight, low price and easy molding. The cornea drug delivery device formed by the one-time compression molding of polymethyl methacrylate has lower cost, is convenient to use and is not easy to crush the eyeball 400.

In particular, during a corneal crosslinking operation, the sterilized corneal administration device is first used, the handle 300 is squeezed, and the gas in the gas chamber 310 is discharged from the gas port 250. Then, the second drug collecting part 200 is brought close to the eyeball 400 of the patient, and the drug collecting port 220 is aligned with the cornea 410, so that the cornea 410 is positioned at the center of the drug collecting port 220. The annular bonding surface 240 is bonded to the conjunctiva, and the air port 250 is covered by the conjunctiva. The handle 300 is released and the corneal drug delivery device is attached to the eyeball 400.

After the cornea administration device is adsorbed on the eyeball 400, the riboflavin solution is dropwise added into the first medicine collecting cavity 110 through the medicine adding port 120, specifically, the riboflavin solution is 0.25% of a riboflavin transdermal formulation solution, and chemical permeation promoters such as ethylenediamine tetraacetic acid, aluminum chlorohydrate and the like can be added into the solution. The riboflavin solution flows into the second drug collecting chamber 210 through the connection port. The riboflavin solution in the drug-collecting cavity is sucked and dipped by the blood-sucking sponge to prevent the liquid medicine from overflowing, the handle 300 is squeezed, and the cornea drug delivery device is taken down lightly. The cornea 410 is then rinsed with physiological saline, and after the riboflavin solution attached to the cornea is rinsed clean, the cornea is dipped again with an aspiratory sponge.

The cornea 410 is irradiated with ultraviolet light A having a wavelength in the range of 370nm + -5 nm for 160s. The diameter of the light spot is preferably 9mm, and the illumination intensity is 45mW/cm ² Energy Density 7.2J/cm ² . Saline is timely added to the cornea 410 in a dropwise manner during irradiation to keep moist. The cornea administration device is suitable for all operations requiring riboflavin solution to soak cornea and ultraviolet rays to irradiate cornea, including de-epithelialization cornea crosslinking, transepithelialization cornea crosslinking, cornea rapid crosslinking combined cornea refractive operation and the like.

In an embodiment, referring to fig. 1 to 7, an air channel 230 is disposed in the second medicine collecting portion 200, and the air channel 230 communicates with the air port 250 and the air cavity 310. In this embodiment, the air channel 230 is disposed in the second medicine collecting portion 200, so that the second medicine collecting portion 200 can be firmly adsorbed on the surface of the eyeball 400 of the patient through the air pressure difference between the inside and the outside of the air channel 230, thereby avoiding the loss of the riboflavin solution, improving the absorption efficiency of the cornea 410, and further enhancing the crosslinking effect.

In one embodiment, referring to fig. 2 to 7, a plurality of air ports 250 are provided and are spaced apart in the circumferential direction of the annular abutment surface 240. In this embodiment, there are five ports 250, although in other embodiments, eight ports 250 or other numbers may be provided. The junction of the annular abutment 240 and the handle 300 is not provided with the air port 250 so that the handle 300 can be oriented toward the corneal flap pedicle when the corneal drug delivery device is attached to the eyeball 400. By providing the plurality of air ports 250, the annular bonding surface 240 can be tightly adsorbed on the surface of the eyeball 400, so that the cornea administration device is fixed, thereby avoiding the loss of riboflavin solution, improving the absorption efficiency of the cornea 410, and further enhancing the crosslinking effect.

In one embodiment, referring to fig. 2-7, the air channel 230 is annular and communicates with each air port 250. In this embodiment, the air channel 230 formed in the annular second medicine collecting portion 200 is annular, so that the second medicine collecting portion 200 is pressed uniformly when being adsorbed on the eyeball 400, and is not easy to fall off, thereby avoiding the loss of riboflavin solution, improving the absorption efficiency of the cornea 410, and further enhancing the crosslinking effect.

In one embodiment, referring to fig. 2-7, the air port 250 is arcuate and extends circumferentially about the annular abutment surface 240. In this embodiment, the air ports 250 are stripe-shaped, and the size and shape of each air port 250 are the same. The strip-shaped arc-shaped air port 250 extending along the circumferential direction of the annular bonding surface 240 can adapt to the shape of the annular bonding surface 240, so that the annular bonding surface 240 is not easy to generate gaps when being bonded with the eyeball 400, the annular bonding surface 240 is tightly adsorbed on the surface of the eyeball 400, and then the cornea administration device is fixed, thereby avoiding the loss of riboflavin solution, improving the absorption efficiency of the cornea 410, and further enhancing the crosslinking effect. In other embodiments, the ports 250 may also be configured in a polygonal shape with different numbers of sides.

In one embodiment, referring to FIGS. 2-7, the spacing between each two adjacent ports 250 is equal. In this embodiment, the intervals between two adjacent air ports 250 are equal, so that the pressure applied to the annular bonding surface 240 when the annular bonding surface is adsorbed on the eyeball 400 is relatively uniform, and a gap is not easy to generate between the annular bonding surface and the surface of the eyeball 400, so that the cornea administration device is fixed, thereby avoiding the loss of riboflavin solution, improving the absorption efficiency of the cornea 410, and further enhancing the crosslinking effect. When the number of the gas ports 250 is set to an even number, each of the gas ports 250 is symmetrically arranged with respect to the center of the annular fitting surface 240.

In an embodiment, referring to fig. 2 to 7 and fig. 9, the annular attaching surface 240 is an arc surface, so as to be capable of attaching to the eyeball 400. In this embodiment, the radian of the annular bonding surface 240 conforms to the natural radian of the eyeball 400 of a person, so as to avoid discomfort of the patient, and the eye 400 is tightly bonded through tear film infiltration, so that the loss of riboflavin solution is avoided, the absorption efficiency of the cornea 410 is improved, and the crosslinking effect is further enhanced.

In one embodiment, referring to fig. 2-7 and 9, the annular abutment surface 240 is a structural member made of a flexible material. In this embodiment, the annular bonding surface 240 is made of a flexible material, so as to avoid discomfort of the patient, and can be tightly bonded with the eyeball 400, thereby avoiding the loss of riboflavin solution, improving the absorption efficiency of the cornea 410, and further enhancing the crosslinking effect. The flexible material may be selected from polymethyl methacrylate.

In an embodiment, referring to fig. 1 to 9, the first medicine collecting chamber 110 is funnel-shaped, and the diameter of the first medicine collecting chamber 110 gradually decreases from the medicine adding port 120 to the connection port. In this embodiment, the diameter of the drug addition port 120 is 25.0mm. The diameter of the connection port was 9.0mm.

In an embodiment, referring to fig. 1 to 8, the second medicine collecting portion 200 is annular, and the second medicine collecting portion 200 has an inner diameter of 9.0mm and an outer diameter of 13.0mm. In this embodiment, the second medicine collecting portion 200 has a circular shape, and the diameter of the medicine collecting opening 220 may be the same as that of the connection opening. The diameter of the drug collecting port 220 is 9.0mm.

The foregoing disclosure is illustrative of the present utility model and is not to be construed as limiting the scope of the utility model, which is defined by the appended claims.

Claims

1. A corneal drug delivery device, comprising: the device comprises an annular body and a handle, wherein the annular body comprises a second medicine collecting part close to an eyeball and a first medicine collecting part far away from the eyeball, the first medicine collecting part is provided with a first medicine collecting cavity, a medicine adding port and a connecting port, the medicine adding port and the connecting port are communicated with the first medicine collecting cavity, the second medicine collecting part is connected with the first medicine collecting part, the second medicine collecting part is provided with a second medicine collecting cavity communicated with the connecting port and a medicine collecting port communicated with the second medicine collecting cavity, the second medicine collecting part is provided with an annular fitting surface at the medicine collecting port, and the handle is connected with the annular body;

2. The corneal drug delivery device of claim 1, wherein an air channel is provided in the second drug-collecting portion, the air channel communicating the air port and the air chamber.

3. The corneal delivery device of claim 2, wherein the plurality of ports are spaced circumferentially about the annular abutment surface.

4. The corneal drug delivery device of claim 3, wherein the airway is annular and communicates with each of the ports.

5. The corneal delivery device of claim 4, wherein the port is arcuate and extends circumferentially of the annular abutment surface.

6. The corneal drug delivery device of claim 4, wherein the spacing between each adjacent two of the ports is equal.

7. The cornea administration apparatus of claim 1, wherein the annular fitting surface is an arcuate surface so as to be capable of fitting with the eyeball.

8. The corneal delivery device of claim 6, wherein the annular abutment surface is a structural member made of a flexible material.

9. The corneal drug delivery device of claim 1, wherein the first drug-collecting cavity is funnel-shaped, and the diameter of the first drug-collecting cavity gradually decreases from the drug-adding port to the connection port.

10. The corneal drug delivery device of claim 1, wherein the second drug-collecting portion is annular, and the second drug-collecting portion has an inner diameter of 9.0mm and an outer diameter of 13.0mm.